Wie können wir helfen?
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
You do not have access to this post.
1445534
{:RT5IT86M}
1
https://www.zotero.org/styles/urban-research-and-practice?source=1
50
default
1
1
3806
http://www.hautkrebs-leitlinien.de/wp-content/plugins/zotpress/